<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-AOT-2737</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2737</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Оценка гуморального иммунного ответа у детей при иммунизации разными типами инактивированных гриппозных вакцин в сезон 2019-2020 года</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of the humoral immune response in children after immunization with different types of inactivated influenza vaccines in the 2019-2020 season</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8394-102X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бузицкая</surname><given-names>Ж. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Buzitskaya</surname><given-names>Zh. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бузицкая Ж.В. – к.б.н., ведущий научный сотрудник лаборатории векторных вакцин </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Buzitskaya Z.V., PhD (Biology), Leading Research Associate, Laboratory of Vector Vaccines </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">janna.buzitskaya@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попов</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Popov</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Попов А.Б. – аспирант </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Popov A.B., Postgraduate Student </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">andrey-popov93@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7560-398X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романовская-Романько</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanovskaya-Romanko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Романовская-Романько Е.А. – к.б.н., старший научный сотрудник лаборатории векторных вакцин </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Romanovskaya-Romanko E.A., PhD (Biology), Senior Research Associate, Laboratory of Vector Vaccines </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">ekaterina.romanovskaya@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0411-9896</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеева</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeeva</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергеева М.В. – к.б.н., ведущий научный сотрудник лаборатории векторных вакцин </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Sergeeva M.V., PhD (Biology), Leading Research Associate, Laboratory of Vector Vaccines </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">maria.sergeeva@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5573-1570</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Варюшина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Varyushina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Варюшина Е.А. – д.б.н., ведущий научный сотрудник лаборатории векторных вакцин </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Varyushina E.A., PhD, MD (Biology), Leading Research Associate, Laboratory of Vector Vaccines </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">elena.varyushina@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1860-3857</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ерофеева</surname><given-names>М. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Erofeeva</surname><given-names>M. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ерофеева М.К. – д.м.н., руководитель лаборатории испытаний новых средств защиты от вирусных инфекций </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Erofeeva M.K., PhD, MD (Medicine), Head, Laboratory of Trials of Novel Remedies for Antiviral Protection </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">mariana.erofeeva@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2127-3820</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стукова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stukova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Стукова М.А. – к.м.н., заведующая лабораторией векторных вакцин </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Stukova M.A., PhD (Medicine), Head, Laboratory of Vector Vaccines </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">marina.stukova@influenza.spb.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3643-7354</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиознов</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lioznov</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лиознов Д.А. – д.м.н., профессор, директор; заведующий кафедрой инфекционных болезней и эпидемиологии </p><p>197376, Санкт-Петербург, ул. Профессора Попова, 15/17</p></bio><bio xml:lang="en"><p>Lioznov D.A., PhD, MD (Medicine), Professor, Director; Head, Department of Infectious Diseases and Epidemiology </p><p>15/17 Professor Popov St., St. Petersburg, 197376</p></bio><email xlink:type="simple">dmitry.lioznov@influenza.spb.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ «Научно-исследовательский институт гриппа имени А.А. Смородинцева» Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">A. Smorodintsev Research Institute of Influenza<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ «Научно-исследовательский институт гриппа имени А.А. Смородинцева» Министерства здравоохранения РФ;&#13;
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">A. Smorodintsev Research Institute of Influenza;&#13;
First St. Petersburg State I. Pavlov Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><fpage>751</fpage><lpage>758</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бузицкая Ж.В., Попов А.Б., Романовская-Романько Е.А., Сергеева М.В., Варюшина Е.А., Ерофеева М.К., Стукова М.А., Лиознов Д.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бузицкая Ж.В., Попов А.Б., Романовская-Романько Е.А., Сергеева М.В., Варюшина Е.А., Ерофеева М.К., Стукова М.А., Лиознов Д.А.</copyright-holder><copyright-holder xml:lang="en">Buzitskaya Z.V., Popov A.B., Romanovskaya-Romanko E.A., Sergeeva M.V., Varyushina E.A., Erofeeva M.K., Stukova M.A., Lioznov D.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2737">https://www.mimmun.ru/mimmun/article/view/2737</self-uri><abstract><p>Грипп является одной из наиболее распространенных респираторных инфекций, вызывающей миллионы случаев заболевания во всем мире. Эффективность вакцинации против гриппа и характер иммунного ответа на препарат могут варьировать в разных возрастных группах и в зависимости от состава вакцины. Поскольку дети подвержены наиболее высокому риску заболевания и являются основными распространителями гриппозной инфекции, исследования иммунологической эффективности вакцин у детей имеют большое значение для контроля эпидемического процесса в целом. Целью данного исследования стала оценка особенностей формирования гуморального иммунного ответа у детей после иммунизации различными типами инактивированных гриппозных вакцин. Наблюдательное исследование было проведено в сезоне 2019-2020 г. и включало 230 детей в возрасте до 18 лет, а также 87 участников в возрасте от 18 до 60 лет в качестве группы сравнения. Добровольцы, давшие информированное согласие на участие, были привиты одним из трех препаратов: «Гриппол Плюс», «Совигрипп» или «Ультрикс», в открытом режиме. Оценку гуморального иммунного ответа проводили по титру антигемагглютинирующих антител в парных сыворотках добровольцев, взятых до и через три недели после вакцинации. Иммуногенность вакцин, проанализированная суммарно по всем препаратам в возрастной группе до 18 лет, удовлетворяла критериям CPMP для оценки инактивированных гриппозных вакцин по показателям кратности прироста антител и доле лиц с сероконверсией в отношении всех трех компонентов (A/H1N1pdm09, A/H3N2 и B/Victoria). У детей в возрасте от 6 до 18 лет наблюдали более активный ответ к компоненту B/Victoria по сравнению со взрослыми участниками (от 18 до 60 лет), которого тем не менее было недостаточно для обеспечения 70%-ной иммунной прослойки лиц с условно защитным титром антител. Сравнительный анализ иммуногенности препаратов, проведенный для подгруппы детей в возрасте от 6 до 18 лет с исходно низким уровнем антител на момент вакцинации, показал, что сплитвакцина «Ультрикс» имела преимущество по сравнению с адъювантной вакциной «Гриппол плюс» в формировании антительного ответа в отношении компонента B/Victoria и не отличалась в отношении компонентов A/H1N1pdm09 и A/H3N2. У детей младше 6 лет наблюдалась тенденция к менее выраженному гуморальному иммунному ответу на вакцинацию по сравнению со старшей возрастной группой, что может быть связано с возрастными особенностями иммунной системы у детей младшего дошкольного возраста.</p></abstract><trans-abstract xml:lang="en"><p>Causing millions of cases worldwide every year, influenza is one of the most common respiratory infections. The effectiveness of influenza vaccination and the nature of the resulting immune response may vary depending on the vaccine composition and age group. Since children are at the highest risk of disease and act as the main carriers of influenza, the assessment of the immunological efficacy of vaccines in this group is crucial for controlling the epidemic. Therefore, this study aimed to evaluate the characteristics of the humoral immune response in children after immunization with various types of inactivated influenza vaccines. An observational study was conducted in the 2019-2020 season and involved 230 children (&lt; 18 years old) and a comparison group of 87 adults aged 18 to 60 years. The subjects, who provided informed consent to participate, were vaccinated with one of three vaccines (Grippol Plus, Sovigripp, or Ultrix) in an open-label fashion. The humoral immune response was assessed by measuring the hemagglutination inhibition (HI) titer in the paired sera taken before and three weeks after vaccination. The immunogenicity of the vaccines in the age group under 18, met the CPMP criteria for the assessment of inactivated influenza vaccines in terms of the fold increase in antibody titers and the proportion of individuals with seroconversion to all three components (A/H1N1pdm09, A/H3N2, and B/Victoria). Although 6 to 18-year-old participants showed a more robust immune response to the B/Victoria component compared to the adult participants (aged 18 to 60), it was insufficient to ensure that 70% of the participants have a protective antibody titer. A comparative analysis of the vaccines’ immunogenicity was carried out for a subgroup of children aged 6-18 who had initially low antibody levels at the time of vaccination. The analysis showed that the split vaccine Ultrix outperformed the adjuvanted vaccine Grippol Plus in generating an antibody response to the component B/Victoria; however, the antibody responses to the A/H1N1pdm09 and A/H3N2 components did not differ between the two vaccines. The children under 6 years of age demonstrated a less pronounced humoral immune response to vaccination compared with the other age groups, which may be due to the age-related characteristics of the immune system in children of preschool age.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инактивированная гриппозная вакцина</kwd><kwd>дети</kwd><kwd>подростки</kwd><kwd>антитела</kwd><kwd>реакция торможения гемагглютинации</kwd><kwd>критерии иммуногенности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>inactivated influenza vaccine</kwd><kwd>children</kwd><kwd>adolescents</kwd><kwd>antibodies</kwd><kwd>hemagglutination inhibition reaction</kwd><kwd>immunogenicity criteria</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена в рамках государственного задания Министерства здравоохранения Российской Федерации по теме «Оценка напряженности коллективного иммунитета и эпидемиологической эффективности гриппозных вакцин в Российской Федерации» на 2018-2021 гг.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>The study was carried out within the government contract of the Ministry of Health of the Russian Federation Assessment of the Intensity of Collective Immunity and Epidemiological Effectiveness of Influenza Vaccines in the Russian Federation (2019-2021).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Black S., Nicolay U., Vesikari T., Knuf M., del Giudice G., della Cioppa G., Tsai T., Clemens R., Rappioli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J., 2011, Vol. 30, no. 12, pp. 1081-1085.</mixed-citation><mixed-citation xml:lang="en">Black S., Nicolay U., Vesikari T., Knuf M., del Giudice G., della Cioppa G., Tsai T., Clemens R., Rappioli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J., 2011, Vol. 30, no. 12, pp. 1081-1085.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">EMA.Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 12 March 1997. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf.</mixed-citation><mixed-citation xml:lang="en">EMA.Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. 12 March 1997. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-harmonisation-requirements-influenza-vaccines_en.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hinojosa M., Shepard S.S., Chung J.R., King J.P., McLean H.Q., Flannery B., Belongia E.A., Levine M.Z. Impact of immune priming, vaccination, and infection on influenza A(H3N2) antibody landscapes in children. J. Infect. Dis., 2021., Vol. 224, pp. 469-480.</mixed-citation><mixed-citation xml:lang="en">Hinojosa M., Shepard S.S., Chung J.R., King J.P., McLean H.Q., Flannery B., Belongia E.A., Levine M.Z. Impact of immune priming, vaccination, and infection on influenza A(H3N2) antibody landscapes in children. J. Infect. Dis., 2021., Vol. 224, pp. 469-480.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J. Hyg. (Lond.), 1972, Vol. 70, pp. 767-777.</mixed-citation><mixed-citation xml:lang="en">Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virus. J. Hyg. (Lond.), 1972, Vol. 70, pp. 767-777.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Krivitskaya V.Z., Kuznetsova E.V., Maiorova V.G., Petrova E.R., Sominina A.A., Danilenko D.M. Influenza vaccination influencing level of specific humoral immunity in healthy individuals. Russian Journal of Infection and Immunity, 2022, Vol. 12, no. 1, pp. 127-141. (In Russ.) doi: 10.15789/2220- 7619-IVI-1750.</mixed-citation><mixed-citation xml:lang="en">Krivitskaya V.Z., Kuznetsova E.V., Maiorova V.G., Petrova E.R., Sominina A.A., Danilenko D.M. Influenza vaccination influencing level of specific humoral immunity in healthy individuals. Russian Journal of Infection and Immunity, 2022, Vol. 12, no. 1, pp. 127-141. (In Russ.) doi: 10.15789/2220- 7619-IVI-1750.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Manenti A., Tete S.M., Mohn K. G.-I., Jul-Larsen Å., Gianchecchi E., Montomoli E., Brokstad K.A., Cox R.J. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine, 2017, Vol. 35, pp. 191-198.</mixed-citation><mixed-citation xml:lang="en">Manenti A., Tete S.M., Mohn K. G.-I., Jul-Larsen Å., Gianchecchi E., Montomoli E., Brokstad K.A., Cox R.J. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination. Vaccine, 2017, Vol. 35, pp. 191-198.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nayak J., Hoy G., Gordon A. Influenza in children. Cold Spring Harb. Perspect. Med., 2021, Vol. 11, a038430. doi: 10.1101/cshperspect.a038430</mixed-citation><mixed-citation xml:lang="en">Nayak J., Hoy G., Gordon A. Influenza in children. Cold Spring Harb. Perspect. Med., 2021, Vol. 11, a038430. doi: 10.1101/cshperspect.a038430</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ng S., Fang V.J., Ip D.K., Chan K.-H., G.M., Peiris J.S.M., Cowling B.J. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J. Infect. Dis., 2013, Vol. 208, no. 8, pp. 1320-1324.</mixed-citation><mixed-citation xml:lang="en">Ng S., Fang V.J., Ip D.K., Chan K.-H., G.M., Peiris J.S.M., Cowling B.J. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J. Infect. Dis., 2013, Vol. 208, no. 8, pp. 1320-1324.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nuñez I.A., Carlock M.A., Allen J.D., Owino S.O., Moehling K.K., Nowalk M.P., Susick M., Diagle K., Sweeney K., Mundle S., Vogel T.U., Delagrave S., Ramgopal M., Zimmerman R.K., Kleanthous H., Ross T.M. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS One, 2017, Vol. 12, no. 11, e0185666. doi: 10.1371/journal.pone.0185666.</mixed-citation><mixed-citation xml:lang="en">Nuñez I.A., Carlock M.A., Allen J.D., Owino S.O., Moehling K.K., Nowalk M.P., Susick M., Diagle K., Sweeney K., Mundle S., Vogel T.U., Delagrave S., Ramgopal M., Zimmerman R.K., Kleanthous H., Ross T.M. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS One, 2017, Vol. 12, no. 11, e0185666. doi: 10.1371/journal.pone.0185666.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Oh Y.N., Kim S., Choi Y.B., Woo S.I., Hahn Y.-S., Lee J.K. Clinical similarities between influenza A and B in children: a single-center study, 2017/18 season. BMC Pediatr., 2019, Vol. 19, 472. doi: 10.1186/s12887-019-1862-3.</mixed-citation><mixed-citation xml:lang="en">Oh Y.N., Kim S., Choi Y.B., Woo S.I., Hahn Y.-S., Lee J.K. Clinical similarities between influenza A and B in children: a single-center study, 2017/18 season. BMC Pediatr., 2019, Vol. 19, 472. doi: 10.1186/s12887-019-1862-3.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Özkaya P.Y.,Turanli E.E., Metin H., Uysal A.A., Çiçek C., Karapinar B.. Severe influenza virus infection in children admitted to the PICU: Comparison of influenza A and influenza B virus infection. J. Med. Virol., 2022, Vol. 94, pp. 575-581.</mixed-citation><mixed-citation xml:lang="en">Özkaya P.Y.,Turanli E.E., Metin H., Uysal A.A., Çiçek C., Karapinar B.. Severe influenza virus infection in children admitted to the PICU: Comparison of influenza A and influenza B virus infection. J. Med. Virol., 2022, Vol. 94, pp. 575-581.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull., 1979, Vol. 35, no. 1, pp. 69-75.</mixed-citation><mixed-citation xml:lang="en">Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull., 1979, Vol. 35, no. 1, pp. 69-75.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Study of population immunity against influenza in the population of the Russian Federation: methodical guideline МУ 3.1.3490-17. Approved by the Chief State Sanitary Doctor of the Russian Federation on October 27, 2017. (In Russ.) Available at: https://www.garant.ru/products/ipo/prime/doc/71723602/.</mixed-citation><mixed-citation xml:lang="en">Study of population immunity against influenza in the population of the Russian Federation: methodical guideline МУ 3.1.3490-17. Approved by the Chief State Sanitary Doctor of the Russian Federation on October 27, 2017. (In Russ.) Available at: https://www.garant.ru/products/ipo/prime/ doc/71723602/.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tsang T.K., Cauchemez S., Perera R.A., Freeman G., Fang V.J., Ip D.K., Leung G.M., Peiris J.S., Cowling B.J. Association between antibody titers and protection against influenza virus infection within households. J. Infect. Dis., 2014, Vol. 210, no. 5, pp. 684-692.</mixed-citation><mixed-citation xml:lang="en">Tsang T.K., Cauchemez S., Perera R.A., Freeman G., Fang V.J., Ip D.K., Leung G.M., Peiris J.S., Cowling B.J. Association between antibody titers and protection against influenza virus infection within households. J. Infect. Dis., 2014, Vol. 210, no. 5, pp. 684-692.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Williams K.V., Zhai B., Alcorn J.F., Nowalk P., Levine M.Z., Kim S.S., Flannery B., Geffel K.M., Merranko A.J., Nagg J.P., Collins M., Susick M., Clarke K.S., Zimmerman R.K., Martin J.M. A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults. Vaccine, 2022, Vol. 40, no. 5, pp. 780-788.</mixed-citation><mixed-citation xml:lang="en">Williams K.V., Zhai B., Alcorn J.F., Nowalk P., Levine M.Z., Kim S.S., Flannery B., Geffel K.M., Merranko A.J., Nagg J.P., Collins M., Susick M., Clarke K.S., Zimmerman R.K., Martin J.M. A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults. Vaccine, 2022, Vol. 40, no. 5, pp. 780-788.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
